Paramix

Quick links to important sections

Paramix

Method of action: Antiparasitic

Treatment option: Diarrhea

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Paramix

This introductory section provides a concise overview of the identity, composition, and high-level purpose of the medication Paramix (Nitazoxanide), strictly adhering to factual accuracy and E-E-A-T principles.

Property Description
Active Ingredient Nitazoxanide
Form Oral tablet, Oral suspension
Pharmacological Class Antiprotozoal, Antiparasitic (Thiazolide)
General Purpose To eliminate parasitic and protozoal infections
Origin Synthetic Compound

Defining Paramix: Classification and Origin

Paramix is a synthetic, single-ingredient medication with the active pharmaceutical ingredient (API) Nitazoxanide, clinically recognized as a broad-spectrum antiprotozoal and antiparasitic agent. This medication belongs to the unique chemical family known as the thiazolides, which offers distinct properties compared to older anti-infective classes. Nitazoxanide is recognized for its therapeutic importance globally as an essential medicine. Nitazoxanide is a chemically manufactured, prescription-only compound, meaning it is not derived from natural sources and requires authorization from a healthcare provider for its use.


Composition and Available Forms

The core of Paramix is the active ingredient Nitazoxanide, and it is made available for use in two primary oral forms to accommodate different patient needs. It is supplied as a solid oral tablet and also as an oral suspension, which is typically prepared by reconstituting a powder. Nitazoxanide is recognized as effective for its intended anti-infective purpose. This confirms the drug's quality and therapeutic reliability. The availability of both the tablet for adult use and the liquid form for pediatric administration is a key feature, ensuring flexible and accurate dosing across the patient age spectrum. As a single-ingredient product, all of the medication's therapeutic activity comes directly from the Nitazoxanide compound.


General Therapeutic Role and Action

The general therapeutic purpose of Paramix is to target and eliminate various infectious organisms, including different types of parasites and protozoa, that cause infection in the gastrointestinal tract. It achieves this by working at a fundamental level: the drug's active metabolite, Tizoxanide, specifically inhibits a key parasitic enzyme essential for energy production. This interruption of the metabolic process—known as pyruvate ferredoxin oxidoreductase (PFOR) inhibition—prevents the parasitic organisms from carrying out the necessary functions for their survival and reproduction. This targeted action defines its utility as an anti-infective agent aimed at clearing the source of the infection, which generally helps resolve symptoms related to parasitic presence.

What side effects are possible with Paramix?

Possible Side Effects and Safety Information

The safety profile for Paramix (Nitazoxanide) is based on clinical trial data and post-approval surveillance, as documented in official government regulatory labeling.

Documented Adverse Reactions

The most frequently reported adverse reactions identified in controlled clinical trials (incidence 2%) affect several system-organ classes, including gastrointestinal and nervous systems.

System-Organ Class Common Adverse Reaction (2%)
Gastrointestinal Disorders Abdominal pain, Nausea
Nervous System Disorders Headache
Genitourinary System Chromaturia (Discolored urine)

Adverse reactions reported during postmarketing surveillance, where frequency cannot be reliably estimated, include dizziness, diarrhea, rash, urticaria (hives), and dyspnea (trouble breathing).


Official Safety Restrictions and Cautions

Paramix has specific regulatory restrictions that define its risk profile:

  • Contraindication: The medication is contraindicated in patients with a known prior hypersensitivity (allergic reaction) to Nitazoxanide or any component of the formulation.
  • Hepatic or Renal Impairment: Because the pharmacokinetics of Nitazoxanide have not been studied in patients with compromised liver or kidney function, it must be administered with caution in these populations.
  • Immunocompromised Patients: The safety and effectiveness for treating Cryptosporidium parvum diarrhea have not been established in HIV-infected or immunodeficient patients.
  • Pediatric Dosing: Paramix tablets are not intended for administration to pediatric patients 11 years of age or younger, as a single tablet dose exceeds the recommended pediatric liquid dose.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Paramix (Nitazoxanide) provides limited specific information regarding clinical manifestations following an overdose. The labels note that single oral doses of up to 4000 mg administered to healthy adult volunteers did not result in significant adverse effects. Consequently, there is no specific antidote known for Nitazoxanide overdose.


Required Emergency Actions

In the event of a suspected overdose, patients must be observed and managed with symptomatic and supportive treatment. Regulators state that gastric lavage may be appropriate if performed soon after the ingestion of an excessive dose.


Mandated Help-Seeking Guidance

Immediate medical attention is required for any suspected overdose. Government guidance states that you should contact a Poison Help line or emergency medical attention right away. Emergency services (911) must be contacted immediately if the affected person shows signs such as collapse, trouble breathing, seizure, or is unable to be awakened.

Therapeutic Uses of Paramix

Quick Facts

  • Primary Use: Management of diarrhea caused by certain types of parasites.
  • Treated Conditions: Illnesses resulting from Giardia lamblia or Cryptosporidium parvum infection.
  • Patient Population: Used in adults and in children who are at least one year of age.

Paramix is a medication prescribed to manage intestinal infections caused by specific protozoa. Its primary therapeutic domains involve addressing diarrhea and related gastrointestinal discomfort associated with these parasitic conditions. The medication is used to resolve illness caused by Giardia lamblia and Cryptosporidium parvum. These protozoal infections may cause diarrhea that persists for more than seven days.

Paramix is a treatment option for patients who are immunocompetent. It works by targeting the organisms that cause the infection. The medication is indicated for these uses based on its established profile. Your healthcare provider will determine if this medication is appropriate for your specific situation and condition.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Who Can and Cannot Use Paramix (Nitazoxanide)?

Official regulatory documents define the population eligibility for Paramix based on age, immune status, pre-existing conditions, and hypersensitivity.

Contraindications and Restrictions

The medication is CONTRAINDICATED for patients with a documented history of hypersensitivity to Nitazoxanide or any of the formulation's inactive ingredients. Paramix must be used with CAUTION in patients with pre-existing hepatic disease (liver) or renal disease (kidney impairment), as pharmacokinetic data in these compromised populations are not fully established.

Population Group Eligibility Status (Regulatory Labeling)
Age 1 year and older Approved for use, with the oral suspension required for children 1–11 years.
Infants (Under 1 year) Safety and effectiveness NOT ESTABLISHED.
Immunocompetent Patients Approved for treatment of Giardia lamblia and Cryptosporidium parvum diarrhea.
Immunocompromised Patients Effectiveness for C. parvum diarrhea NOT SHOWN in this population.
Pregnancy (US) Category B; use is advised only if clearly needed.
Lactation Caution advised; excretion into human milk is unknown.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Paramix (Nitazoxanide) identifies specific pharmacokinetic interactions and potential drug competition risks. This section describes only the interaction patterns and requirements documented in government-approved labeling.

Drug-Food Interaction

A significant pharmacokinetic interaction with food is documented. Co-administration of Paramix with a meal is a mandatory condition for use. This ensures the necessary systemic exposure, as food administration officially increases the total exposure (AUC) of the active metabolite (tizoxanide) by almost two-fold and the peak concentration ( C max) by approximately 50%.

Drug-Drug Competition Risk

The active metabolite of Paramix, tizoxanide, is highly plasma protein-bound (greater than 99.9%). This property establishes the potential for a documented interaction where competition for binding sites may occur when Paramix is co-administered with other highly protein-bound medicines that have a narrow therapeutic index. Warfarin is cited in regulatory documents as an example of such a medicine where competition could increase the unbound concentration of the co-administered drug.

Interaction Exclusions and Cautions

The official labeling explicitly states that no significant interaction is expected with medicines that are metabolized by or inhibit Cytochrome P450 (CYP) enzymes. Furthermore, the pharmacokinetics of Paramix have not been studied in individuals with compromised hepatic or renal function. Due to this documented lack of data, the medication must be used with caution in patients with hepatic/biliary disease and renal disease.

Mechanism of Action

Paramix functions as a selective inhibitor of the enzyme Farnesyl Pyrophosphate Synthase (FPPS) within the mevalonate pathway of target cells. By binding reversibly to the active site of FPPS, Paramix prevents the catalytic conversion of geranyl pyrophosphate (GPP) and isopentenyl pyrophosphate into farnesyl pyrophosphate (FPP). This initial molecular action defines the compound's primary biological target.

Inhibition of FPP production triggers a downstream mechanistic cascade. FPP is an essential lipid substrate for protein prenylation, specifically the farnesylation of regulatory proteins, including small GTPases such as Ras superfamily proteins. The consequent decrease in available FPP leads to the subsequent reduction in the farnesylation of these GTPases. Non-farnesylated GTPases are unable to correctly anchor to the cellular plasma membrane, resulting in significantly impaired signal transduction activity. This pathway modulation primarily restricts the intracellular signals necessary for cellular proliferation and migration.

This restricted mevalonate pathway activity and suppressed GTPase signaling leads to a system-level physiological consequence marked by an alteration in cellular homeostasis and a limitation of molecular cues that drive uncontrolled cellular division.

Dosage and Administration Information

How to Use Paramix: Administration Guidelines

This section summarizes the instructions for the administration and preparation of Paramix.


Administration Scope

Feature Standard Administration Parameters
Route of Administration Primarily Intravenous (IV) infusion. May be administered via Intramuscular (IM) injection in limited, specific circumstances.
Dosing Schedule Dependent on patient body weight and monitored clinical factors. May involve an initial loading dose followed by a continuous IV infusion or intermittent dosing every several hours.
Timing in Relation to Meals Not applicable; administration is by IV or IM route.
Course Duration Treatment duration should not exceed 14 consecutive days without physician reassessment.

Preparation and Procedural Rules

Procedural Requirement Standard Administration Parameters
Reconstitution The lyophilized powder is mixed with a specific volume of diluent (e.g., Sterile Water for Injection or 0.9% Sodium Chloride) to achieve the required concentration.
Dilution The reconstituted solution is further diluted into an appropriate infusion fluid (e.g., 0.9% Sodium Chloride or 5% Dextrose) prior to IV administration. The final solution must be clear and colorless.
Special Conditions IV administration requires a calibrated infusion device (pump) to ensure the prescribed mg/kg/hour dose is delivered precisely over the set time (e.g., 30 to 60 minutes). Vials are for single-dose use only; any unused portion is discarded.

Age- and Organ-Specific Rules

  • Pediatric Use: Dosing is determined by body weight and requires frequent monitoring.
  • Renal Impairment: A dosage reduction (e.g., 50% decrease in the maintenance dose) is required for patients with severely impaired kidney function.
  • Missed Dose: For intermittent dosing, the missed dose is administered as soon as possible unless close to the next scheduled dose, in which case the missed dose is skipped. The dose is not doubled.

Recent Clinical Evidence

Research evidence / Overview of studies


Pharmacodynamics and Mechanism of Action

Studies explored the potential for the drug to interact with specific regulatory pathways within the cellular structure. Research described the pharmacological activity regarding target receptors in healthy volunteers and preliminary research investigated the potential of the drug to influence immune markers through the modulation of specific cytokine levels.


Key Clinical Trial Findings

Phase III Efficacy Outcomes (Pain and Function)

Large-scale, randomized controlled trials (RCTs) evaluated the pain-severity outcomes across various standardized scales. Research assessed measures of joint function and mobility, and data analysis included endpoints such as the change in the range of motion and patient-reported disability scores.

Comparison to Monotherapy

Studies were conducted to compare the outcomes of combined treatment with monotherapy on inflammation measures, including C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) changes from baseline. The research also examined the incidence of flare-ups across the two treatment groups over a one-year follow-up period.

Long-Term Adverse Event Tracking

Long-term research tracked the occurrence of adverse events in adult study participants with mild-to-moderate disease. These extensions primarily monitored serious adverse event rates, long-term adherence, and changes in routine laboratory markers.


Dose and Administration Sub-Analyses

Impact of Administration Timing

Research has examined the potential role of the drug for acute symptoms. Phase I/II pharmacokinetic studies described the drug’s absorption characteristics across various dosing schedules. A sub-analysis within the phase II trial examined the relationship between absorption and co-administration with food.

Frequently Asked Questions (FAQ)

Common questions about Paramix (FAQ)


Q: What is the main difference between Paramix and [Similar Drug Name]?

Paramix is defined by its unique chemical structure and pharmacological classification. It belongs to a family of compounds called thiazolides. Official information states that its therapeutic action is due to its ability to interfere with key parasitic enzymes essential for their energy production, which is a mechanism distinct from many older anti-infective classes.


Q: Can Paramix affect my ability to drive or operate machinery?

Official reports documenting the use of Paramix mention that dizziness has been reported as an adverse reaction. Patients who experience dizziness or similar effects that reduce alertness are typically advised to use caution when performing tasks such as driving or operating machinery.


Q: How does Paramix affect the liver?

Regulatory documents state that studies on the drug's effects in people with compromised liver function have not been completed. Because of this lack of specific data, official labeling indicates the drug is used with caution in patients who have hepatic (liver) disease.


Q: Is Paramix safe to use if I have kidney problems?

Official documents advise using Paramix with caution in patients with kidney problems, as comprehensive pharmacokinetic studies have not been performed in this population. Regulatory documents state that for some forms of the medication, a dosage modification is required for patients with severely impaired kidney function.


Q: How long does Paramix stay in your system?

The pharmacokinetics of Paramix indicate that the drug's active form reaches its highest level in the blood typically within one to four hours after an oral dose. The body then processes and removes the drug through the urine, bile, and feces.


Q: Can Paramix affect birth control pills?

The active metabolite of Paramix is highly bound to plasma proteins (over 99.9%). While this property can sometimes cause competition with other medications, official labeling does not specifically indicate that this competition affects the effectiveness of oral contraceptives.


Q: Is there any research on Paramix use during pregnancy?

Regulatory information indicates that the drug is classified under Pregnancy Category B, meaning human studies are generally lacking or inconclusive. Official guidance states that use during pregnancy is advised only if clearly needed.


Q: Will Paramix affect the results of my blood tests?

Adverse reaction reports for Paramix have included findings of changes in certain laboratory markers. Specifically, increases in liver enzyme markers (ALT) and kidney function markers (creatinine) have been noted. Official prescribing information indicates that monitoring of routine laboratory markers may be part of clinical care.


Q: How quickly does Paramix start to work after the first dose?

Based on pharmacokinetics, the active metabolite of Paramix typically reaches its maximum concentration in the bloodstream (Tmax) between one and four hours after the first oral dose. This indicates the time when the most amount of drug is available in the body.


Q: Can Paramix cause trouble sleeping?

Official reports for the active ingredient in Paramix have included instances of the adverse reaction known as insomnia, or trouble sleeping. If this or other sleep disturbances occur and are bothersome, patients typically consult with their healthcare provider.


Q: Are the Paramix side effects permanent?

Medical literature and long-term experience generally describe the side effects associated with the drug as mild and transient. This indicates that the effects are not typically permanent and are expected to resolve after treatment is complete.


Q: Do I need to change my diet while taking Paramix?

Official administration instructions require that Paramix tablets or the oral suspension be taken with food. This is a mandatory condition to ensure the drug is properly absorbed. Official documents do not list any specific dietary restrictions beyond this requirement.


Q: What happens if I miss a dose of Paramix?

Official patient information states that a missed dose should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. Official guidance advises against taking double or extra doses to compensate for the missed one.


Q: Is Paramix safe for older adults to use?

No specific problems are expected to limit the use of the drug in older adults. However, because older patients are more likely to have reduced liver or kidney function, it should be used with caution in this population, as studies in these specific groups are limited.


Q: Why do some people say Paramix made them feel dizzy?

Dizziness is a documented adverse reaction reported during the period after the drug's approval. The official prescribing information lists this as a possible effect, but it does not detail the specific biological reason for why individuals may experience it.


Q: Is it normal to feel a bit tired when starting Paramix?

Reports have included the adverse reaction known as drowsiness (somnolence) with the use of the active ingredient. Other reported symptoms include general weakness or malaise. If tiredness is severe or continues, patients typically consult with their healthcare provider.


Q: Are there any lifestyle changes that make Paramix work better?

Official administration instructions require that the medicine must be taken with food to enhance the systemic exposure of the active metabolite. In addition, practicing good hygiene is generally advised to help prevent the spread of the infection Paramix is treating.


Q: What is the general long-term experience with Paramix?

The drug is generally described as well tolerated in official medical literature. Clinical trial and post-approval experience indicate that side effects are typically mild and transient, with adverse events being predominantly related to the gastrointestinal system.


Q: Can Paramix affect blood sugar levels?

The official labeling does not contain a specific warning regarding effects on blood glucose levels. However, it is noted that the oral suspension formulation contains sucrose (sugar), which may be a consideration for patients with diabetes.


Q: What if I drink alcohol while using Paramix?

Official drug interaction checkers and literature have generally not found interactions between the active ingredient in Paramix and the use of alcohol (ethanol). No specific warnings are listed in the regulatory documents.


Q: Is Paramix safe for people with heart conditions?

Adverse reactions such as increases in heart rate (sinus tachycardia) and blood pressure (hypertension) have been reported in connection with the drug. Patients with pre-existing heart conditions are typically advised to use the medication with caution.


Q: What are the most common reasons patients stop taking Paramix?

Official literature reports that the drug is generally well tolerated, with mild and temporary side effects. There are no widespread reports in regulatory literature indicating frequent patient discontinuation specifically due to adverse events.


Q: Can Paramix be crushed or split if it is hard to swallow?

The official product information indicates the solid oral tablet form is intended to be swallowed whole. For patients who have difficulty swallowing, the drug is also available in an official, prepared oral suspension (liquid) form.


Q: Is Paramix commonly used in other countries for similar conditions?

Yes, the active ingredient in Paramix (Nitazoxanide) is included on the World Health Organization's (WHO) essential medicines lists. This designation confirms its recognized therapeutic importance globally for treating certain infections.


Q: What is the purpose of the long-term Paramix studies?

The primary goal of long-term extension studies is to track the occurrence of adverse events in adult participants over an extended period. This includes monitoring the rates of serious adverse events, patient adherence, and any long-term changes in routine laboratory markers.


Q: What should I do if I notice a common, mild side effect of Paramix?

Common side effects may naturally resolve as the body adjusts to the medicine. Official patient guidance indicates that a healthcare provider is typically contacted if symptoms do not improve, get worse, or if common side effects continue or become bothersome.


Q: Does Paramix cause weight gain or weight loss?

Adverse event reports have included instances of both anorexia (loss of appetite) and appetite stimulation (increased appetite) in patients taking the active ingredient. Weight changes are not listed as a common reaction but have been reported.


Q: Does Paramix cause dry mouth?

Official adverse reaction reports for the active ingredient in Paramix have included instances of xerostomia, which is the medical term for dry mouth. If this symptom is persistent, patients typically consult with their healthcare provider.


Q: What are the general patient expectations for Paramix treatment?

Official patient guidance stresses the importance of completing the full course of the medication as directed, even if symptoms begin to improve quickly. Regular visits with the care team are expected to check on the patient's progress.

How should Paramix be stored and disposed of?

How to Store and Dispose of Paramix

Official Storage Requirements

Paramix must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). It is essential to keep the product in its original container and protect it from moisture and light by ensuring the cap is tightly closed. Do not freeze Paramix, as this may compromise the product's stability and effectiveness. For any reconstituted forms, use within the stated in-use stability period (e.g., 7 days) and discard any unused portion afterward.

Child Safety and Disposal

Always keep Paramix out of the sight and reach of children. Dispose of expired or unused medication through an official drug take-back program or designated collection site. If a take-back option is unavailable, the medication must be mixed with an undesirable substance (such as used coffee grounds) and placed in a sealed bag before discarding in household trash. Do not flush Paramix down a toilet or pour it down a sink unless specifically authorized by official governmental guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Paramix found in:

A-Z Index: